GMED
Rank #161Rank #161 by gross profitability (GP/assets 0.36) · ROE 11.4% · Piotroski F-Score 8 / 9.
As-of 2026-07-22 · CIK 0001237831 · all metrics point-in-time as of the filing date.
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-20 | 2023-12-31filed 2024-02-21 | 2022-12-31filed 2023-02-21 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 276.8 | 254.0 | 144.7 | 68.3 |
| Stock-based compensation | 49.8 | 54.2 | 52.7 | 32.8 |
| Change in receivables | 52.2 | 78.1 | 49.9 | 50.8 |
| Change in inventory | 17.6 | 29.9 | 70.3 | 61.7 |
| Change in payables | 8.5 | 17.7 | (14.2) | 14.4 |
| Operating cash flow | 753.4 | 520.6 | 243.5 | 178.5 |
| Investing | ||||
| Capital expenditures | 164.7 | 115.4 | 78.3 | 74.0 |
| Acquisitions, net of cash | 252.5 | 17.6 | 296.0 | 31.4 |
| Investing cash flow | (355.0) | (176.1) | 303.0 | (110.4) |
| Financing | ||||
| Share repurchases | 300.5 | 85.8 | 225.6 | 144.5 |
| Financing cash flow | (679.2) | (27.7) | (231.8) | (110.0) |
| Summary | ||||
| Free cash flow | 588.8 | 405.2 | 165.2 | 104.4 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?